Data from A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes

Abstract

<div>AbstractPurpose:<p>A subset of primary prostate cancer expresses programmed death-ligand 1 (PD-L1), but whether they have a unique tumor immune microenvironment or genomic features is unclear.</p>Experimental Design:<p>We selected PD-L1–positive high-grade and/or high-risk primary prostate cancer, characterized tumor-infiltrating lymphocytes with multiplex immunofluorescence, and identified genomic alterations in immunogenic and nonimmunogenic tumor foci.</p>Results:<p>One quarter of aggressive localized prostate cancer cases (29/115) had tumor PD-L1 expression more than 5%. This correlated with increased density of CD8<sup>+</sup> T cells, a large fraction coexpressing PD-1, versus absent PD-1 expression on sparse CD8 T cells in unselected cases. Most CD8<sup>+</sup>PD-1<sup>+</sup> cells did not express terminal exhaustion markers (TIM3 or LAG3), while a subset expressed TCF1. Consistent with these CD8<sup>+</sup>PD-1<sup>+</sup>TCF1<sup>+</sup> cells being progenitors, they were found in antigen-presenting cell niches in close proximity to MHC-II<sup>+</sup> cells. CD8 T-cell density in immunogenic prostate cancer and renal cell carcinoma (RCC) was nearly identical. Shallow <i>RB1</i> and <i>BRCA2</i> losses, and deep deletions of <i>CHD1</i>, were prevalent, the latter being strongly associated with a dendritic cell gene set in The Cancer Genome Atlas. Tumor mutation burden was variable; neither high microsatellite instability nor <i>CDK12</i> alterations were present.</p>Conclusions:<p>A subset of localized prostate cancer is immunogenic, manifested by PD-L1 expression and CD8<sup>+</sup> T-cell content comparable with RCC. The CD8<sup>+</sup> T cells include effector cells and exhausted progenitor cells, which may be expanded by immune checkpoint inhibitors (ICI). Genomic losses of <i>RB1, BRCA2</i>, and <i>CHD1</i> may be drivers of this phenotype. These findings indicate that immunotherapies may be effective in biomarker-selected subpopulations of patients with localized prostate cancer.</p></div>